as well as in anaemia failing an erythropoiesis stimulating agent that requires two or more RBC units over eight week in adult patients with IPSS-R myelodyplastic syndrome with ring sideroblasts ...

Moreover, while Reblozyl was only cleared for use as second-line therapy in MDS patients with ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus ...